Preservatives in eyedrops: The good, the bad and the ugly

Progress in Retinal and Eye Research

Volumn 29, Issue 4, 2010, Pages 312-334

  Baudouin, Christophe ^a,b,c,d,f   Labbé, Antoine ^a,b,c,d,f   Liang, Hong ^a,b,c,d   Pauly, Aude ^b,c,d   Brignole Baudouin, Françoise ^b,c,d,e  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CNRS   (France)

^e Department of Toxicology   (France)

^f LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; BENZALKONIUM CHLORIDE; CYTOKINE; EYE DROPS; LIPID; PRESERVATIVE;

ALLERGY; APOPTOSIS; CELL LOSS; CELL MEMBRANE; CHEMICAL INTERACTION; CLINICAL RESEARCH; COMORBIDITY; CONJUNCTIVAL SQUAMOUS METAPLASIA; CONJUNCTIVITIS; CORNEA EPITHELIUM; CORNEA SURFACE IMPAIRMENT; CYTOKINE RELEASE; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG EXPOSURE; EYE DISCOMFORT; EYE DISEASE; EYE INJURY; GLAUCOMA; GLAUCOMA SURGERY; GOBLET CELL; HISTOPATHOLOGY; HUMAN; IMMUNOREACTIVITY; INFLAMMATION; LONG TERM CARE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL METAPLASIA; SUBCONJUNCTIVAL FIBROSIS; TEAR FILM; TOXICITY; TREATMENT FAILURE;

ANIMALS; BENZALKONIUM COMPOUNDS; DRY EYE SYNDROMES; EYE DISEASES; HUMANS; HYPERSENSITIVITY; MODELS, BIOLOGICAL; OPHTHALMIC SOLUTIONS; PRESERVATIVES, PHARMACEUTICAL; TEARS;

EID: 77953359918     PISSN: 13509462     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2010.03.001     Document Type: Review

References (141)

1. Alm A., Camras C.B., Watson P.G. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv. Ophthalmol. 1997, 41(Suppl 2):S105-S110.
2. Baudouin C. A new approach for better comprehension of diseases of the ocular surface. J. Fr. Ophtalmol. 2007, 30:239-246.
3. Baudouin C., de Lunardo C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br. J. Ophthalmol. 1998, 82:39-42.
4. Baudouin C., Garcher C., Haouat N., Bron A., Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology 1994, 101:454-460.
5. Baudouin C., Hamard P., Liang H., Creuzot-Garcher C., Bensoussan L., Brignole F. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology 2004, 111:2186-2192.
6. Baudouin C., Liang H., Bremond-Gignac D., Hamard P., Hreiche R., Creuzot-Garcher C., Warnet J.M., Brignole-Baudouin F. CCR 4 and CCR 5 expression in conjunctival specimens as differential markers of T(H)1/T(H)2 in ocular surface disorders. J. Allergy Clin. Immunol. 2005, 116:614-619.
7. Baudouin C., Liang H., Hamard P., Riancho L., Creuzot-Garcher C., Warnet J.M., Brignole-Baudouin F. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology 2008, 115:109-115.
8. Baudouin C., Pisella P.J., Fillacier K., Goldschild M., Becquet F., De Saint Jean M., Bechetoille A. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999, 106:556-563.
9. Baudouin C., Riancho L., Warnet J.M., Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest. Ophthalmol. Vis. Sci. 2007, 48:4123-4128.
10. Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008, 86:716-726.
11. Beasley R., Burgess C., Holt S. Call for worldwide withdrawal of benzalkonium chloride from nebulizer solutions. J. Allergy Clin. Immunol. 2001, 107:222-223.
12. Brandt J.D., Wittpenn J.R., Katz L.J., Steinmann W.N., Spaeth G.L. Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Am. J. Ophthalmol. 1991, 112:297-301.
13. Brandt J.D. Does benzalkonium chloride cause cataract?. Arch. Ophthalmol. 2003, 121:892-893.
14. Brasnu E., Brignole-Baudouin F., Riancho L., Guenoun J.M., Warnet J.M., Baudouin C. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr. Eye. Res. 2008, 33:303-312.
15. Brasnu E., Brignole-Baudouin F., Riancho L., Warnet J.M., Baudouin C. Comparative study on the cytotoxic effects of benzalkonium chloride on the Wong-Kilbourne derivative of Chang conjunctival and IOBA-NHC cell lines. Mol. Vis. 2008, 14:394-402.
16. Brignole-Baudouin F., Ott A.C., Warnet J.M., Baudouin C. Flow cytometry in conjunctival impression cytology: a new tool for exploring ocular surface pathologies. Exp. Eye Res. 2004, 78:473-481.
17. Broadway D.C., Chang L.P. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J. Glaucoma 2001, 10:237-249.
18. Broadway D.C., Grierson I., O'Brien C., Hitchings R.A. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch. Ophthalmol. 1994, 112:1437-1445.
19. Broadway D.C., Grierson I., O'Brien C., Hitchings R.A. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch. Ophthalmol. 1994, 112:1446-1454.
20. Bron A., Chiambaretta F., Pouliquen P., Rigal D., Rouland J.F. Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension. J. Fr. Ophtalmol. 2003, 26:668-674.
21. Buron N., Micheau O., Cathelin S., Lafontaine P.O., Creuzot-Garcher C., Solary E. Differential mechanisms of conjunctival cell death induction by ultraviolet irradiation and benzalkonium chloride. Invest. Ophthalmol. Vis. Sci. 2006, 47:4221-4230.
22. Campagna P., Macri A., Rolando M., Calabria G. Chronic topical eye preservative-free beta-blocker therapy effect on the ocular surface in glaucomatous patients. Acta Ophthalmol. Scand. Suppl. 1997, 224:53.
23. Champeau E., Edelhauser H. Effect of ophthalmic preservatives on the ocular surface: conjunctival and corneal uptake and distribution of benzalkonium chloride and chlorhexidine digluconate. The Preocular Tear Film 1986, Dry Eye Institute, Inc, Lubbock, TX. F. Holly (Ed.).
24. Chandrasekaran S., Cumming R.G., Rochtchina E., Mitchell P. Associations between elevated intraocular pressure and glaucoma, use of glaucoma medications, and 5-year incident cataract: the Blue Mountains Eye Study. Ophthalmology 2006, 113:417-424.
25. Charnock C. Are multidose over-the-counter artificial tears adequately preserved?. Cornea 2006, 25:432-437.
26. Chibret H. Conservateurs et préparation ophtalmiques: réalités et perspectives. Ann. Pharmaceutiques Françaises 1997, 55:228-231.
27. Chung S.H., Lee S.K., Cristol S.M., Lee E.S., Lee D.W., Seo K.Y., Kim E.K. Impact of short-term exposure of commercial eyedrops preserved with benzalkonium chloride on precorneal mucin. Mol. Vis. 2006, 12:415-421.
28. Ciancaglini M., Carpineto P., Agnifili L., Nubile M., Fasanella V., Lanzini M., Calienno R., Mastropasqua L. An in vivo confocal microscopy and impression cytology analysis of preserved and unpreserved levobunolol-induced conjunctival changes. Eur. J. Ophthalmol. 2008, 18:400-407.
29. Cohen J.S., Gross R.L., Cheetham J.K., VanDenburgh A.M., Bernstein P., Whitcup S.M. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv. Ophthalmol. 2004, 49(Suppl 1):S45-S52.
30. Curren R.D., Harbell J.W. Ocular safety: a silent (in vitro) success story. Altern. Lab. Anim. 2002, 30(Suppl. 2):69-74.
31. de Jong C., Stolwijk T., Kuppens E., de Keizer R., van Best J. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 1994, 232:221-224.
32. De Saint Jean M., Baudouin C., Di Nolfo M., Roman S., Lozato P., Warnet J.M., Brignole F. Comparison of morphological and functional characteristics of primary-cultured human conjunctival epithelium and of Wong-Kilbourne derivative of Chang conjunctival cell line. Exp. Eye. Res. 2004, 78:257-274.
33. De Saint Jean M., Brignole F., Bringuier A.F., Bauchet A., Feldmann G., Baudouin C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest. Ophthalmol. Vis. Sci. 1999, 40:619-630.
34. De Saint Jean M., Debbasch C., Brignole F., Rat P., Warnet J.M., Baudouin C. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr. Eye Res. 2000, 20:85-94.
35. Debbasch C., Brignole F., Pisella P.J., Warnet J.M., Rat P., Baudouin C. Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest. Ophthalmol. Vis. Sci. 2001, 42:642-652.
36. Debbasch C., Pisella P.J., De Saint Jean M., Rat P., Warnet J.M., Baudouin C. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta-blockers on Chang conjunctival cells. Invest. Ophthalmol. Vis. Sci. 2001, 42:2525-2533.
37. Debbasch C., De La Salle S.B., Brignole F., Rat P., Warnet J.M., Baudouin C. Cytoprotective effects of hyaluronic acid and Carbomer 934P in ocular surface epithelial cells. Invest. Ophthalmol. Vis. Sci. 2002, 43:3409-3415.
38. Denis P., Demailly P., Saraux H. Clinical evaluation of betaxolol in ophthalmic suspension with or without preservative agent in patients with glaucoma or ocular hypertension. J. Fr. Ophtalmol. 1993, 16:297-303.
39. Deutschle T., Porkert U., Reiter R., Keck T., Riechelmann H. In vitro genotoxicity and cytotoxicity of benzalkonium chloride. Toxicol. In Vitro 2006, 20:1472-1477.
40. Diebold Y., Calonge M., Enriquez de Salamanca A., Callejo S., Corrales R.M., Saez V., Siemasko K.F., Stern M.E. Characterization of a spontaneously immortalized cell line (IOBA-NHC) from normal human conjunctiva. Invest. Ophthalmol. Vis. Sci. 2003, 44:4263-4274.
41. Dogan A.S., Orhan M., Soylemezoglu F., Irkec M., Bozkurt B. Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients. Clin. Exper. Ophthalmol. 2004, 32:62-66.
42. Dong J.Q., Babusis D.M., Welty D.F., Acheampong A.A., Tang-Liu D., Whitcup S.M. Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbits. J. Ocul. Pharmacol. Ther. 2004, 20:285-292.
43. Doucet O., Lanvin M., Zastrow L. A new in vitro human epithelial model for assessing eye irritating potential of formulated cosmetic products. In Vitro Mol. Toxicol. 1998, 11:273-283.
44. Doucet O., Lanvin M., Thillou C., Linossier C., Pupat C., Merlin B., Zastrow L. Reconstituted human corneal epithelium: a new alternative to the Draize eye test for the assessment of the eye irritation potential of chemicals and cosmetic products. Toxicol. In Vitro 2006, 20:499-512.
45. Draize J., Woodward G., Calvery H. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J. Pharmacol. Exp. Ther. 1944, 82:377-390.
46. Dry Eye WorkShop The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul. Surf. 2007, 5:75-92.
47. Dry Eye WorkShop The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul. Surf. 2007, 5:93-107.
48. Easty D.L., Nemeth-Wasmer G., Vounatsos J.P., Girard B., Besnainou N., Pouliquen P., Delval L., Rouland J.F. Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients. Br. J. Ophthalmol. 2006, 90:574-578.
49. Epstein S.P., Ahdoot M., Marcus E., Asbell P.A. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J. Ocul. Pharmacol. Ther. 2009, 25:113-119.
50. EMEA public statement on antimicrobial preservatives in ophthalmic preparations for human use. EMEA/622721/2009, London, 8 December 2009.
51. Erb C., Gast U., Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246:1593-1601.
52. Fellman R.L., Sullivan E.K., Ratliff M., Silver L.H., Whitson J.T., Turner F.D., Weiner A.L., Davis A.A. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology 2002, 109:998-1008.
53. Ferk F., Misik M., Hoelzl C., Uhl M., Fuerhacker M., Grillitsch B., Parzefall W., Nersesyan A., Micieta K., Grummt T., Ehrlich V., Knasmuller S. Benzalkonium chloride (BAC) and dimethyldioctadecyl-ammonium bromide (DDAB), two common quaternary ammonium compounds, cause genotoxic effects in mammalian and plant cells at environmentally relevant concentrations. Mutagenesis 2007, 22:363-370.
54. Friedlaender M.H., Breshears D., Amoozgar B., Sheardown H., Senchyna M. The dilution of benzalkonium chloride (BAK) in the tear film. Adv. Ther. 2006, 23:835-841.
55. Gardner W.P., Girard J.E. Analysis of common household cleaner-disinfectants by capillary elektrophoresis. J. Chem. Educ. 2000, 77:1335-1338.
56. Gedde S.J., Schiffman J.C., Feuer W.J., Herndon L.W., Brandt J.D., Budenz D.L., Tube Versus Trabeculectomy Study Group Three-year follow-up of the tube versus trabéculectomie study. Am. J. Ophthalmol. 2009, 148:670-684.
57. Gobbels M., Spitznas M. Influence of artificial tears on corneal epithelium in dry-eye syndrome. Graefes Arch. Clin. Exp. Ophthalmol. 1989, 227:139-141.
58. Gobbels M., Spitznas M. Corneal epithelial permeability of dry eyes before and after treatment with artificial tears. Ophthalmology 1992, 99:873-878.
59. Goto Y., Ibaraki N., Miyake K. Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol. Arch. Ophthalmol. 2003, 121:835-839.
60. Gross R.L., Peace J.H., Smith S.E., Walters T.R., Dubiner H.B., Weiss M.J., Ochsner K.I. Duration of IOP reduction with travoprost BAK-free solution. J. Glaucoma 2008, 17:217-222.
61. Guenoun J.M., Baudouin C., Rat P., Pauly A., Warnet J.M., Brignole-Baudouin F. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest. Ophthalmol. Vis. Sci. 2005, 46:4594-4599.
62. Guenoun J.M., Baudouin C., Rat P., Pauly A., Warnet J.M., Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest. Ophthalmol. Vis. Sci. 2005, 46:2444-2450.
63. Hamacher T., Airaksinen J., Saarela V., Liinamaa M.J., Richter U., Ropo A. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol. Suppl. (Oxf) 2008, 242:14-19.
64. Hamard P., Blondin C., Debbasch C., Warnet J.M., Baudouin C., Brignole F. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch. Clin. Exp. Ophthalmol. 2003, 241:1037-1043.
65. Henry J.C., Peace J.H., Stewart J.A., Stewart W.C. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin. Ophthalmol. 2008, 2:613-621.
66. Herman D.C., Gordon M.O., Beiser J.A., Chylack L.T., Lamping K.A., Schein O.D., Soltau J.B., Kass M.A. Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study. Am. J. Ophthalmol. 2006, 142:800-810.
67. Herreras J.M., Pastor J.C., Calonge M., Asensio V.M. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 1992, 99:1082-1088.
68. Hommer A. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur. J. Ophthalmol. 2007, 17:53-62.
69. Hong S., Lee C.S., Seo K.Y., Seong G.J., Hong Y.J. Effects of topical antiglaucoma application on conjunctival impression cytology specimens. Am. J. Ophthalmol. 2006, 142:185-186.
70. Ichijima H., Petroll W.M., Jester J.V., Cavanagh H.D. Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride. Cornea 1992, 11:221-225.
71. Ishibashi T., Yokoi N., Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J. Glaucoma 2003, 12:486-490.
72. Jaenen N., Baudouin C., Pouliquen P., Manni G., Figueiredo A., Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur. J. Ophthalmol. 2007, 17:341-349.
73. Kahook M.Y., Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv. Ther. 2008, 25:743-751.
74. Kass M.A., Heuer D.K., Higginbotham E.J., Johnson C.A., Keltner J.L., Miller J.P., Parrish R.K., Wilson M.R., Gordon M.O. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 2002, 120:701-713.
75. Khoh-Reiter S., Jessen B.A. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. BMC Ophthalmol. 2009, 9:5.
76. Kim M.S., Choi C.Y., Kim J.M., Chang H.R., Woo H.Y. Microbial contamination of multiply used preservative-free artificial tears packed in reclosable containers. Br. J. Ophthalmol. 2008, 92:1518-1521.
77. Kuppens E.V., de Jong C.A., Stolwijk T.R., de Keizer R.J., van Best J.A. Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Br. J. Ophthalmol. 1995, 79:339-342.
78. Labbe A., Dupas B., Hamard P., Baudouin C. In vivo confocal microscopy study of blebs after filtering surgery. Ophthalmology 2005, 112:1979-1986.
79. Labbe A., Nicola R.D., Dupas B., Auclin F., Baudouin C. Epithelial basement membrane dystrophy: evaluation with the HRT II Rostock Cornea Module. Ophthalmology 2006, 113:1301-1308.
80. Labbe A., Pauly A., Liang H., Brignole-Baudouin F., Martin C., Warnet J.M., Baudouin C. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J. Ocul. Pharmacol. Ther. 2006, 22:267-278.
81. Labbe A., Niaudet P., Loirat C., Charbit M., Guest G., Baudouin C. In vivo confocal microscopy and anterior segment optical coherence tomography analysis of the cornea in nephropathic cystinosis. Ophthalmology 2009, 116:870-876.
82. Laibovitz R., Zimmerman K., Getson A., Shedden A., Laurence J., Adamsons I. Comparison of the efficacy and tolerability of preservative-free 2.0% dorzolamide/0.5% timolol and 2.0% dorzolamide/0.5% timolol. Invest. Ophthalmol. Vis. Sci. 1999, 40:S665.
83. Lavappa K.S. Survey of ATCC stocks of human cell lines for HeLa contamination. In Vitro 1978, 14:469-475.
84. Lavin M.J., Wormald R.P., Migdal C.S., Hitchings R.A. The influence of prior therapy on the success of trabeculectomy. Arch. Ophthalmol. 1990, 108:1543-1548.
85. Leal B.C., Medeiros F.A., Medeiros F.W., Santo R.M., Susanna R. Conjunctival hyperemia associated with bimatoprost use: a histopathologic study. Am. J. Ophthalmol. 2004, 138:310-313.
86. Leung E.W., Medeiros F.A., Weinreb R.N. Prevalence of ocular surface disease in glaucoma patients. J. Glaucoma 2008, 17:350-355.
87. Lewis R.A., Katz G.J., Weiss M.J., Landry T.A., Dickerson J.E., James J.E., Hua S.Y., Sullivan E.K., Montgomery D.B., Wells D.T., Bergamini M.V. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J. Glaucoma 2007, 16:98-103.
88. Liang H., Baudouin C., Dupas B., Brignole-Baudouin F. Live conjunctiva-associated lymphoid associated tissue (CALT) analysis in rabbit using in vivo confocal microscopy (IVCM) under inflammatory stimuli. Invest. Ophthalmol. Vis. Sci. Oct 22 2009, (Epub ahead of print).
89. Liang H., Baudouin C., Pauly A., Brignole-Baudouin F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br. J. Ophthalmol. 2008, 92:1275-1282.
90. Liang H., Brignole-Baudouin F., Rabinovich-Guilatt L., Mao Z., Riancho L., Faure M.O., Warnet J.M., Lambert G., Baudouin C. Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits. Mol. Vis. 2008, 14:204-216.
91. Lipener C. A randomized clinical comparison of OPTI-FREE EXPRESS and ReNu MultiPLUS multipurpose lens care solutions. Adv. Ther. 2009, 26:435-446.
92. Majumdar S., Hippalgaonkar K., Repka M.A. Effect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea. Int. J. Pharm. 2008, 348:175-178.
93. Martone G., Frezzotti P., Tosi G.M., Traversi C., Mittica V., Malandrini A., Pichierri P., Balestrazzi A., Motolese P.A., Motolese I., Motolese E. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am. J. Ophthalmol. 2009, 147:725-735.
94. Meloni M., Pauly A., Servi B.D., Varlet B.L., Baudouin C. Occludin gene expression as an early in vitro sign for mild eye irritation assessment. Toxicol. In Vitro Sep 1 2009, (Epub ahead of print).
95. Metz D.P., Hingorani M., Calder V.L., Buckley R.J., Lightman S.L. T-cell cytokines in chronic allergic eye disease. J. Allergy Clin. Immunol. 1997, 100:817-824.
96. Miyake K., Ibaraki N., Goto Y., Oogiya S., Ishigaki J., Ota I., Miyake S. ESCRS Binkhorst lecture 2002: pseudophakic preservative maculopathy. J. Cataract Refract. Surg. 2003, 29:1800-1810.
97. Moreno M., Villena A., Cabarga C., Sanchez-Font E., Garcia-Campos J. Impression cytology of the conjunctival epithelium after antiglaucomatous treatment with latanoprost. Eur. J. Ophthalmol. 2003, 13:553-559.
98. Mundorf T., Wilcox K.A., Ousler G.W., Welch D., Abelson M.B. Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes. Adv. Ther. 2003, 20:329-336.
99. Nelson J.D., Havener V.R., Cameron J.D. Cellulose acetate impressions of the ocular surface. Dry eye states. Arch. Ophthalmol. 1983, 101:1869-1872.
100. Nguyen D.H., Beuerman R.W., De Wever B., Rosdy M. Alternative Toxicological Methods 2003, 147-159. CRC Press. H. Salem, S. Katz (Eds.).
101. Noecker R.J., Herrygers L.A., Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004, 23:490-496.
102. Nordmann J.P., Auzanneau N., Ricard S., Berdeaux G. Vision related quality of life and topical glaucoma treatment side effects. Health Qual. Life Outcomes 2003, 1:75.
103. Nuzzi R., Finazzo C., Cerruti A. Adverse effects of topical antiglaucomatous medications on the conjunctiva and the lachrymal (Brit. Engl) response. Int. Ophthalmol. 1998, 22:31-35.
104. Nuzzi R., Vercelli A., Finazzo C., Cracco C. Conjunctiva and subconjunctival tissue in primary open-angle glaucoma after long-term topical treatment: an immunohistochemical and ultrastructural study. Graefes Arch. Clin. Exp. Ophthalmol. 1995, 233:154-162.
105. Osborne S.A., Montgomery D.M., Morris D., McKay I.C. Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye (Lond) 2005, 19:129-137.
106. Patarca R., Rosenzwei J.A., Zuniga A.A., Fletcher M.A. Benzalkonium salts: effects on G protein-mediated processes and surface membranes. Crit. Rev. Oncog. 2000, 11:255-305.
107. Pauloin T., Dutot M., Warnet J.M., Rat P. In vitro modulation of preservative toxicity: high molecular weight hyaluronan decreases apoptosis and oxidative stress induced by benzalkonium chloride. Eur. J. Pharm. Sci. 2008, 34:263-273.
108. Pauly A., Brignole-Baudouin F., Guenoun J.M., Riancho L., Rat P., Warnet J.M., Baudouin C. Comparative study of topical anti-allergic eye drops on human conjunctiva-derived cells: responses to histamine and IFN gamma and toxicological profiles. Graefes Arch. Clin. Exp. Ophthalmol. 2007, 245:534-546.
109. Pauly A., Brignole-Baudouin F., Labbe A., Liang H., Warnet J.M., Baudouin C. New tools for the evaluation of toxic ocular surface changes in the rat. Invest. Ophthalmol. Vis. Sci. 2007, 48:5473-5483.
110. Pauly A., Labbe A., Baudouin C., Liang H., Warnet J.M., Brignole-Baudouin F. In vivo confocal microscopic grading system for standardized corneal evaluation: application to toxic-induced damage in rat. Curr. Eye Res. 2008, 33:826-838.
111. Pauly A., Meloni M., Brignole-Baudouin F., Warnet J.M., Baudouin C. Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Invest. Ophthalmol. Vis. Sci. 2009, 50:1644-1652.
112. Pawar P.K., Majumdar D.K. Effect of formulation factors on in vitro permeation of moxifloxacin from aqueous drops through excised goat, sheep, and buffalo corneas. AAPS Pharm. Sci. Tech. 2006, 7:E13.
113. Pellinen P., Lokkila J. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost. Ophthalmic. Res. 2009, 41:118-122.
114. Pisella P.J., Debbasch C., Hamard P., Creuzot-Garcher C., Rat P., Brignole F., Baudouin C. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest. Ophthalmol. Vis. Sci. 2004, 45:1360-1368.
115. Pisella P.J., Fillacier K., Elena P.P., Debbasch C., Baudouin C. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic. Res. 2000, 32:3-8.
116. Pisella P.J., Pouliquen P., Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br. J. Ophthalmol. 2002, 86:418-423.
117. Rathore M.S., Majumdar D.K. Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops. AAPS Pharm. Sci. Tech. 2006, 7:57.
118. Rodrigues Mde L., Felipe Crosta D.P., Soares C.P., Deghaide N.H., Duarte R., Sakamoto F.S., Furtado J.M., Paula J.S., Donadi E.A., Soares E.G. Immunohistochemical expression of HLA-DR in the conjunctiva of patients under topical prostaglandin analogs treatment. J. Glaucoma 2009, 18:197-200.
119. Rolando M., Brezzo V., Giordano G., Campagna P., Burlando S., Calabria G. The effect of different benzalkonium chloride concentrations on human normal ocular surface. The Lacrimal System 1991, Kugler and Ghedini Publications, Amsterdam, Berkely, Milano. O. Van Bijsterveld, M. Lemp, D. Spinelli (Eds.).
120. Rolle U., Chertin B., Puri P. Effects of benzalkonium chloride treatment on the intramural innervation of the upper urinary tract. BJU Int. 2003, 91:683-686.
121. Rosenthal R.A., Buck S.L., Henry C.L., Schlech B.A. Evaluation of the preserving efficacy of lubricant eye drops with a novel preservative system. J. Ocul. Pharmacol. Ther. 2006, 22:440-448.
122. Rossi G.C., Tinelli C., Pasinetti G.M., Milano G., Bianchi P.E. Dry eye syndrome-related quality of life in glaucoma patients. Eur. J. Ophthalmol. 2009, 19:572-579.
123. Samples J.R., Binder P.S., Nayak S. The effect of epinephrine and benzalkonium chloride on cultured corneal endothelial and trabecular meshwork cells. Exp. Eye. Res. 1989, 49:1-12.
124. Schwab I.R., Linberg J.V., Gioia V.M., Benson W.H., Chao G.M. Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. Ophthalmology 1992, 99:197-202.
125. Sherwood M.B., Grierson I., Millar L., Hitchings R.A. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology 1989, 96:327-335.
126. Souchier M., Buron N., Lafontaine P.O., Bron A.M., Baudouin C., Creuzot-Garcher C. Trefoil factor family 1, MUC5AC and human leucocyte antigen-DR expression by conjunctival cells in patients with glaucoma treated with chronic drugs: could these markers predict the success of glaucoma surgery?. Br. J. Ophthalmol. 2006, 90:1366-1369.
127. Swan K.C. Reactivity of the ocular tissues to wetting agents. Am. J. Ophthalmol. 1944, 27:1118-1122.
128. Tasli H., Cosar G. Microbial contamination of eye drops. Cent. Eur. J. Public Health 2001, 9:162-164.
129. Teping C., Wiedemann B. The COMOD system. A preservative-free multidose container for eyedrops. Klin. Monbl. Augenheilkd 1994, 205:210-217.
130. Terai N., Schlotzer-Schrehardt U., Lampel J., Bohm A.G., Rummelt C., Schmidt E., Pillunat L.E. Effect of latanoprost and timolol on the histopathology of the human conjunctiva. Br. J. Ophthalmol. 2009, 93:219-224.
131. Thorne J.E., Anhalt G.J., Jabs D.A. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology 2004, 111:45-52.
132. Uter W., Lessmann H., Geier J., Schnuch A. Is the irritant benzalkonium chloride a contact allergen? A contribution to the ongoing debate from a clinical perspective. Contact Dermatitis 2008, 58:359-363.
133. Uusitalo H., Kaarniranta K., Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol. Suppl. (Oxf) 2008, 242:7-13.
134. Uusitalo, H., Chen, E., Pfeiffer, N., Brignole-Baudouin, F., Kaarniranta, K., Leino, M., et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol., in press.
135. van der Valk R., Webers C.A., Schouten J.S., Zeegers M.P., Hendrikse F., Prins M.H. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005, 112:1177-1185.
136. Wilhelmus K.R. The Draize eye test. Surv. Ophthalmol. 2001, 45:493-515.
137. Wilson W.S., Duncan A.J., Jay J.L. Effect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and man. Br. J. Ophthalmol. 1975, 59:667-669.
138. Yalvac I.S., Gedikoglu G., Karagoz Y., Akgun U., Nurozler A., Koc F., Kasim R., Duman S. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol. Scand. 1995, 73:246-248.
139. Yenice I., Mocan M.C., Palaska E., Bochot A., Bilensoy E., Vural I., Irkec M., Hincal A.A. Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea. Exp. Eye Res. 2008, 87:162-167.
140. Yu A.L., Fuchshofer R., Kampik A., Welge-Lussen U. Effects of oxidative stress in trabecular meshwork cells are reduced by prostaglandin analogues. Invest. Ophthalmol. Vis. Sci. 2008, 49:4872-4880.
141. Zimmerman T.J., Hahn S.R., Gelb L., Tan H., Kim E.E. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J. Ocul. Pharmacol. Ther. 2009, 25:145-152.